Career & Filing History
Every role Rahul D. Ballal has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Rahul D. Ballal holds the role of Director at AGIOS PHARMACEUTICALS, INC. (AGIO). Ballal's filing history also covers Enliven Therapeutics, Inc. (ELVN). Ballal has reported 5 insider filings with the SEC since 2024. The most recent filing was in June 2026.
Every role Rahul D. Ballal has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
AGIOS PHARMACEUTICALS, INC. (AGIO)1 filingUpdated Aug 30, 2026
Rahul D. Ballal is Director of AGIOS PHARMACEUTICALS, INC. (AGIO). 5 SEC Form 4 filings on record going back to 2024, most recently on 23 June 2026. Most recent open-market trade: sold $89K of AGIO on 12 November 2024. Lifetime open-market sales: $1.41M.
Every recent SEC Form 4 transaction Rahul D. Ballal has reported, most recent first.
InsiderAlpha's records for Rahul D. Ballal go back to 2024: 5 primary Form 4 filings, an average of 1.7 per year. 14 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Rahul D. Ballal files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Rahul D. Ballal is a corporate insider, tracked as Director of AGIOS PHARMACEUTICALS, INC. (AGIO). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
1 primary Form 4 filing in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases and 6 open-market sales ($1.41M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$AGIO AGIOS PHARMACEUTICALS, INC.1.5K shares @ $59.21$89K